FTC Sues Endo Pharma for Allegedly Paying Off Generic Drugmakers

Published: Apr 01, 2016

* FTC Sues Endo Pharmaceuticals Inc. And Others For Illegally Blocking Lower-Cost Generic Versions Of The Branded Drugs Opana Er And Lidoderm

* Suit alleges Endo entered into pay-for-delay patent settlements with Impax and Watson to delay generic entry; endo partner settles

* Complaint alleges that Endo paid Impax Laboratories, inc. And Watson Laboratories, inc. To eliminate the risk of competition for opana er and lidoderm

Back to news